China approves use of Roche arthritis drug for some Covid-19 patients


  • China
  • Wednesday, 04 Mar 2020

BEIJING (Reuters): China will use a Roche Holding AG arthritis drug to treat some coronavirus patients in severe condition, health authorities said on Wednesday (March 4), as the country seeks to build up treatment regimens to help the infected recover.

Tocilizumab, sold by the Swiss pharma giant under the trade name Actemra, can be prescribed to coronavirus patients who show serious lung damage and an elevated level of a protein called Interleukin 6, which could indicate inflammation or immunological diseases, the National Health Commission said in the latest version of its treatment guidelines published online.

Actemra can help contain inflammation related to Interleukin 6, according to Roche.

There is no clinical trial evidence yet that the drug will be effective on coronavirus patients, however. Actemra also has not received approval from China's National Medical Product Administration to be sold for use for coronavirus infections.

Chinese researchers recently registered a three-month clinical trial for Actemra that would recruit 188 coronavirus patients and take place from Feb 10 to May 10, according to records shown on China's clinical trials registration database.

Roche could not be immediately reached for comment. The firm said on Monday it donated 14 million yuan (S$2.8 million) worth of Actemra in February.

The firm said in January it expects sales and profits growth this year as demand for new drugs and more business in China offsets declines in older medicines whose patents have expired.

Chinese drugmakers have been racing to develop alternatives to Roche's treatment. Bio-Thera Solutions expects to file new drug approval for its Actemra biosimilar in 2021, and Zhejiang Hisun Pharmaceutical Co received in 2016 regulatory approval to conduct clinical trials for its Tocilizumab candidate, company filings showed.

Biosimilars are cheaper versions of complex biotech drugs such as Actemra. - Reuters

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 1
Cxense type: free
User access status: 3

China , Roche , covid-19 , arthritis , drug

   

Did you find this article insightful?

Yes
No

100% readers found this article insightful

Next In Regional

To avoid tech’s antitrust troubles, India tries a hard 30% cap
China drafts rules on mobile apps’ collection of personal data
Covid-19: Cases up by 1,472, bringing total to 67,169 (updated daily)
China’s top watchdog vows ‘special’ oversight of fintech giants
Amnesty: Facebook, Google becoming ‘human rights-free zones’ in Vietnam
Amnesty: Vietnam steps up online crackdown, jailed activists at record high
Covid-19: Thailand steps up contact tracing after three quarantine flouters test positive
Universal Studios to open US$580mil Nintendo park in February
QAnon’s rise in Japan shows the conspiracy theory’s global spread
China’s livestreamers use fake traffic and virtual gifts to draw real eyeballs

Stories You'll Enjoy